Histopathological and Immunohistochemical Evaluation of Malignant Ovarian Tumours
DOI:
https://doi.org/10.51253/pafmj.v74i1.5949Keywords:
Histopathology, Granulosa cell tumor, Dysgerminoma Leydig cell tumor, Ovarian neoplasms, Sertoli cell tumorAbstract
Objective: To determine the frequency and histological types of malignant ovarian tumours using morphological features and immunohistochemistry.
Study Design: Cross-sectional study.
Place and Duration of Study: Department of Histopathology, Army Medical College, Rawalpindi Pakistan, Jan 2016 to Dec
2018.
Methodology: Newly diagnosed cases of malignant ovarian tumour who had not received chemotherapy were included.
Cases of benign ovarian tumours and those who were treated with pre-surgical chemotherapy were excluded.
Results: In total, 118 cases of malignant ovarian tumours were evaluated. High-grade serous carcinomas were 61(51.7%),
which outnumber others, followed by granulosa cell tumours 17(14.4%), germ cell tumours 13(11%), endometrioid carcinoma 9(7.6%), clear cell carcinoma 4(3.4%), mucinous carcinoma 4(3.4%), low-grade serous carcinoma 2(1.7%) and carcinosarcoma in one case (0.8%). Cancer in the ovary was metastatic in 7(5.9%) cases. No Sertoli Leydig cell tumour, malignant Brenner tumour, embryonal carcinoma or immature teratomas were diagnosed.
Conclusion: Surface epithelial tumours were the most common malignancy, followed by granulosa cell tumours and
dysgerminoma. An increase in the frequency of ovarian tumours in younger age groups was also noted. Immunohistochemistry was a useful adjuvant diagnostic tool in cases of ovarian malignancy. Metastases to the ovary were
mostly gastrointestinal in origin.
Downloads
References
Stewart SL. Ovarian Cancer Incidence: Current and
Comprehensive Statistics. Ovarian Cancer - Clinical and
Therapeutic Perspectives. IntechOpen Limited, London; 2012.
http://dx.doi.org/10.5772/29758.
Kommoss S, Gilks CB, du Bois A, Kommoss F. Ovarian carcinoma
diagnosis: the clinical impact of 15 years of change. Br J Cancer
; 115(8): 993-999. http://doi.org/10.1038/bjc.2016.273.
Verma N, Kumar M, Sagar M, Babu S, Singhai A, Singh N, et al.
Expression of estrogen receptor, progesterone receptor, and
human epidermal growth factor receptor type 2/neu in surface
epithelial ovarian tumors and its clinichistopathological
correlation. Indian J Health Sci Biomed Res 2018; 11(1):19.
Duraiyan J, Govindarajan R, Kaliyappan K. Applications of
immunohistochemistry. J Pharm Bioallied Sci 2012; 4(Suppl 2):
S307-309. http://doi.org/10.4103/0975-7406.100281.
Yemelyanova AV, Vang R, Judson K, Wu LS, Ronnett BM.
Distinction of primary and metastatic mucinous tumors
involving the ovary: analysis of size and laterality data by
primary site with reevaluation of an algorithm for tumor
classification. Am J Surg Pathol 2008; 32(1): 128-138.
http://doi.org/10.1097/PAS.0b013e3180690d2d.
Coburn SB, Bray F, Sherman ME, Trabert B. International patterns
and trends in ovarian cancer incidence, overall and by histologic
subtype. Int J Cancer 2017; 140(11): 2451-2460.
http://doi.org/10.1002/ijc.30676.
Köbel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L,
et al. An immunohistochemical algorithm for ovarian carcinoma
typing. Int J Gynecol Pathol 2016; 35(5): 430-441.
http://doi.org/10.1097/PGP.0000000000000274.
Lin F, Liu H. Immunohistochemistry in undifferentiated
neoplasm/tumor of uncertain origin. Arch Pathol Lab Med 2014;
(12): 1583-1610. http://doi.org/10.5858/arpa.2014-0061-RA.
Sheikh S, Bashir H, Farooq S, Beigh A, Manzoor F, Reshi R, et al.
Histopathological spectrum of ovarian tumours from a referral
hospital in Kashmir valley, Jammu and Kashmir, India. Int J Res
Med Sci 2017; 5(5): 2110–2114.
https://doi.org/10.18203/2320-6012.ijrms20171852.
Patel AS, Patel JM, Shah KJ. Ovarian tumors-Incidence and
histopathological spectrum in tertiary care center, Valsad. Int
Arch Integr Med 2018; 5(2): 84-93.
Zubair M, Hashmi SN, Afzal S, Muhammad I, Din HU, Hamdani
SN. Ovarian Tumours: A study of 2146 Cases at AFIP,
Rawalpindi, Pakistan. Aust Asian J Cancer 2015; 14(1): 21-26.
Razi S, Ghoncheh M, Mohammadian-Hafshejani A, Aziznejhad
H, Mohammadian M, Salehiniya H. The incidence and mortality
of ovarian cancer and their relationship with the Human
Development Index in Asia. Ecancermedicalscience 2016; 10: 628.
https://doi.org/10.3332/ecancer.2016.628.
Zhao L, Guo M, Sneige N, Gong Y. Value of PAX8 and WT1
Immunostaining in Confirming the Ovarian Origin of Metastatic
Carcinoma in Serous Effusion Specimens. Am J Clin Pathol 2012;
(2): 304-309.
https://doi.org/10.1309/AJCPU0FION3RKKFO.
Kommoss F, Gilks CB. Pathology of Ovarian Cancer: Recent
Insights Unveiling Opportunities in Prevention. Clin Obstet
Gynecol 2017; 60(4): 686-696.
https://doi.org/10.1097/GRF.0000000000000314.
Jelovac D, Armstrong DK. Recent progress in the diagnosis and
treatment of ovarian cancer. CA Cancer J Clin 2011; 61(3): 183-
https://doi.org/10.3322/caac.20113.
Köbel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, et
al. Ovarian carcinoma histotype determination is highly
reproducible, and is improved through the use of
immunohistochemistry. Histopathology 2014; 64(7): 1004-1013.
https://doi.org/10.1111/his.12349.
Hashmi AA, Hussain ZF, Bhagwani AR, Edhi MM, Faridi N,
Hussain SD, et al. Clinicopathologic features of ovarian
neoplasms with emphasis on borderline ovarian tumors: an
institutional perspective. BMC Res Notes 2016; 9: 205.
https://doi.org/10.1186/s13104-016-2015-5.
Nishal AJ, Naik KS, Modi J. Analysis of spectrum of ovarian
tumours: a study of 55 cases. Int J Res Med Sci 2015; 3(10): 2714-
http://doi.org/10.18203/2320-6012.ijrms20150820.
Modepalli N, Venugopal SB. Clinicopathological Study of Surface
Epithelial Tumours of the Ovary: An Institutional Study. J Clin
Diagn Res 2016; 10(10): EC01-EC04.
http://doi.org/10.7860/JCDR/2016/21741.8716.
Li Q, Zeng X, Cheng X, Zhang J, Ji J, Wang J, et al. Diagnostic
value of dual detection of hepatocyte nuclear factor 1 beta (HNF1β) and napsin A for diagnosing ovarian clear cell carcinoma. Int
J Clin Exp Pathol 2015; 8(7): 8305-8310.
Kao YC, Lin MC, Lin WC, Jeng YM, Mao TL. Utility of hepatocyte
nuclear factor‐1β as a diagnostic marker in ovarian carcinomas
with clear cells. Histopathology 2012; 61(5): 760-768.
https://doi.org/10.1111/j.1365-2559.2012.04267.x.
DeLair D, Han G, Irving JA, Leung S, Ewanowich CA, Longacre
TA, et al. HNF-1β in ovarian carcinomas with serous and clear
cell change. Int J Gynecol Pathol 2013; 32(6): 541-546.
Downloads
Published
Issue
Section
How to Cite
